Immune-checkpoint inhibitor therapy response evaluation using oncophysics-based mathematical models
- PMID: 36148978
- PMCID: PMC11824897
- DOI: 10.1002/wnan.1855
Immune-checkpoint inhibitor therapy response evaluation using oncophysics-based mathematical models
Abstract
The field of oncology has transformed with the advent of immunotherapies. The standard of care for multiple cancers now includes novel drugs that target key checkpoints that function to modulate immune responses, enabling the patient's immune system to elicit an effective anti-tumor response. While these immune-based approaches can have dramatic effects in terms of significantly reducing tumor burden and prolonging survival for patients, the therapeutic approach remains active only in a minority of patients and is often not durable. Multiple biological investigations have identified key markers that predict response to the most common form of immunotherapy-immune checkpoint inhibitors (ICI). These biomarkers help enrich patients for ICI but are not 100% predictive. Understanding the complex interactions of these biomarkers with other pathways and factors that lead to ICI resistance remains a major goal. Principles of oncophysics-the idea that cancer can be described as a multiscale physical aberration-have shown promise in recent years in terms of capturing the essence of the complexities of ICI interactions. Here, we review the biological knowledge of mechanisms of ICI action and how these are incorporated into modern oncophysics-based mathematical models. Building on the success of oncophysics-based mathematical models may help to discover new, rational methods to engineer immunotherapy for patients in the future. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
Keywords: cancer; immunotherapy; mathematical model; oncology; oncophysics.
© 2022 The Authors. WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals LLC.
Conflict of interest statement
CONFLICT OF INTEREST
The authors have declared no conflicts of interest for this article. Eugene Koay reports consulting work with AstraZeneca, RenovoRx, iO Life Sciences, and Quantum Aurea Capital. He also has royalties from Taylor and Francis LLC for an authored book. His sponsored research includes funding from NIH, DOD, Breakthrough Cancer, Stand Up2Cancer, GE Healthcare, Philips Healthcare, Nanobiotix, and EMD Serono.
Figures

Similar articles
-
Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy.Front Immunol. 2024 Mar 8;15:1368749. doi: 10.3389/fimmu.2024.1368749. eCollection 2024. Front Immunol. 2024. PMID: 38524135 Free PMC article. Review.
-
Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future Perspectives.Int J Mol Sci. 2024 Jun 30;25(13):7252. doi: 10.3390/ijms25137252. Int J Mol Sci. 2024. PMID: 39000359 Free PMC article. Review.
-
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.Cancer Gene Ther. 2020 Dec;27(12):841-853. doi: 10.1038/s41417-020-0174-y. Epub 2020 Apr 28. Cancer Gene Ther. 2020. PMID: 32341410 Review.
-
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.Annu Rev Pathol. 2021 Jan 24;16:223-249. doi: 10.1146/annurev-pathol-042020-042741. Epub 2020 Nov 16. Annu Rev Pathol. 2021. PMID: 33197221 Review.
-
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.J Immunother Cancer. 2022 Jan;10(1):e003024. doi: 10.1136/jitc-2021-003024. J Immunother Cancer. 2022. PMID: 35078922 Free PMC article. Review.
Cited by
-
Investigating tumor-host response dynamics in preclinical immunotherapy experiments using a stepwise mathematical modeling strategy.Math Biosci. 2023 Dec;366:109106. doi: 10.1016/j.mbs.2023.109106. Epub 2023 Nov 4. Math Biosci. 2023. PMID: 37931781 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
- U54 CA210181/CA/NCI NIH HHS/United States
- U54CA210181/CA/NCI NIH HHS/United States
- R01 CA218004/CA/NCI NIH HHS/United States
- R01CA218004/CA/NCI NIH HHS/United States
- U01CA196403/CA/NCI NIH HHS/United States
- U01CA200468/CA/NCI NIH HHS/United States
- U01 CA196403/CA/NCI NIH HHS/United States
- U01CA214263/CA/NCI NIH HHS/United States
- U01 CA200468/CA/NCI NIH HHS/United States
- U01 CA230997/CA/NCI NIH HHS/United States
- P30CA016672/CA/NCI NIH HHS/United States
- P30 CA016672/CA/NCI NIH HHS/United States
- P50 CA221707/CA/NCI NIH HHS/United States
- U01 CA214263/CA/NCI NIH HHS/United States
- P50CA221707/CA/NCI NIH HHS/United States
- R01CA221971/CA/NCI NIH HHS/United States
- R01 CA221971/CA/NCI NIH HHS/United States
- R01 CA195524/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical